Trump administration pressure on Big Pharma to focus investment on the US has raised concerns in Europe, and specifically the ...

Spherix Global Insights’ latest Special Topix™: Neurology Pipeline Opportunities 2025 (US) service captures forward-looking insights from 79 U.S. neurologists across five key neurological ...

Fintel reports that on November 3, 2025, Bernstein maintained coverage of Biogen (NasdaqGS:BIIB) with a Market Perform ...

Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights into the mechanism of ...

Lumeris, a leader in healthcare technology and services, today announced the formation of a coalition - Collaborative for Healthy Rural America (CHRA)tm. Formed to help state leaders accelerate their ...

Manifold will use its tissue-targeting shuttle technology to help Roche develop new therapeutics for diseases of the central nervous system.

Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results this Monday after the bell. Here’s what to ...

Givinostat is an oral histone deacetylase (HDAC) inhibitor approved by the FDA in 2024 to treat Duchenne patients ages 6 ...

The technology company is also opening two new international offices for the agency.

Recursion, Roche and Genentech unveiled the latest product of their nearly four-year artificial intelligence drug discovery collaboration. GSK ’s Blenrep was approved by the FDA for treatment of ...

Garg, recently named to BioSpace’s 40 Under 40, proved her mettle managing one of the toughest partnerships out there: the ...

Discover Biogen's Q3 2025 earnings: 67% launch product growth, strategic pipeline expansion, and updated guidance amid evolving market dynamics.